ACTR-37. SHORT-TERM BEVACIZUMAB FOR RECURRENT GLIOBLASTOMAS

Survival benefit of bevacizumab (BEV) could not be confirmed for recurrent glioblastomas in EORTC 26101, while BEV is commonly chosen at recurrence due to its positive effect in daily life. BEV is usually repeated until tumor progression or adverse events, but the benefit of continuation of BEV is n...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neuro Oncol
Asıl Yazarlar: Matsutani, Tomoo, Hirono, Seiichiro, Iwadate, Yasuo
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2018
Konular:
Abstracts
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216360/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.070
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller